-
Rivaroxaban, sold
under the
brand name
Xarelto among others, is an
anticoagulant medication (blood thinner) used to
treat and
prevent blood clots. Specifically...
- antagonists. Reynolds,
Matthew R. (February 2013). "Discontinuation of
Rivaroxaban:
Filling in the Gaps" (editorial comment). J. Am. Coll. Cardiol. 61 (6):...
-
drugs from the
class of
direct Xa
inhibitors are
marketed worldwide.
Rivaroxaban (Xarelto) was the
first approved FXa
inhibitor to
become commercially...
-
coagulation factors (the
directly acting oral anticoagulants: dabigatran,
rivaroxaban, apixaban, and edoxaban).
Theories on the
coagulation of
blood have existed...
-
include direct thrombin inhibitor (dabigatran) and
factor Xa
inhibitor (
rivaroxaban, apixaban,
betrixaban and edoxaban), and they have been
shown to be as...
-
brand name
Andexxa among others, is an
antidote for the
medications rivaroxaban and apixaban, when
reversal of
anticoagulation is
needed due to uncontrolled...
-
gross revenue. In 2019,
identified "key growth"
products were
Xarelto (
rivaroxaban),
Eylea (aflibercept),
Stivarga (regorafenib),
Xofigo (radium-223), and...
-
blood thinners is the
standard treatment.
Typical medications include rivaroxaban, apixaban, and warfarin.
Beginning warfarin treatment requires an additional...
-
overwhelming reduction in
bleeding as
compared to a
direct oral
anticoagulant (
rivaroxaban) in
patients with
atrial fibrillation and a moderate-to-high risk of...
-
people with
atrial fibrillation (AF).
Direct factor Xa
inhibitors include rivaroxaban,
apixaban and edoxaban, and are
types of
direct oral
anticoagulant (DOAC)...
